Why Did Salesforce Stock Drop After a Strong Quarter?
Popular customer relationship management platform provider Salesforce (NYSE:CRM) has been…
Sell
46
CLYM Quote, Financials, Valuation and Earnings
Last price:
$1.28
Seasonality move
:
18.75%
Day range:
$1.25 - $1.33
52-week range:
$1.05 - $11.55
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.40x
Volume:
91.3K
Avg. volume:
149.4K
1-year change:
-84.86%
Market cap:
$85.7M
Revenue:
--
EPS (TTM):
-$2.13
Analysts' Opinion
-
Consensus RatingClimb Bio has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $10.00, Climb Bio has an estimated upside of 687.4% from its current price of $1.27.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $10.00 representing 100% downside risk from its current price of $1.27.
Fair Value
-
According to the consensus of 1 analyst, Climb Bio has 687.4% upside to fair value with a price target of $10.00 per share.
CLYM vs. S&P 500
-
Over the past 5 trading days, Climb Bio has underperformed the S&P 500 by -2.84% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Climb Bio does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Climb Bio has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Climb Bio reported revenues of --.
Earnings Growth
-
Climb Bio has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Climb Bio reported earnings per share of -$0.13.
Enterprise value:
-65.2M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
4.19x
Price / Operating cash flow:
3,451.99x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$45.1M | -$40.3M | -$82M | -$5.1M | -$10.9M | |
| EBITDA | -$45.1M | -$40.3M | -$82M | -$5.1M | -$10.9M | |
| Diluted EPS | -$1.72 | -$1.31 | -$2.13 | -$0.13 | -$0.13 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $22M | $148.3M | $134.4M | $110.3M | $154.9M | |
| Total Assets | $24.6M | $173.2M | $135M | $110.5M | $217.2M | |
| Current Liabilities | $3.1M | $6M | $6.1M | $2.8M | $4.9M | |
| Total Liabilities | $3.1M | $6M | $6.3M | $2.9M | $5.3M | |
| Total Equity | $21.6M | $167.2M | $128.7M | $107.6M | $211.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$37.4M | -$20.6M | -$15.6M | -$947K | -$5.5M | |
| Cash From Investing | $34.4M | $69M | -$121.1M | $36.7M | -$53.4M | |
| Cash From Financing | -- | $841K | $130.7M | $288K | $41K | |
| Free Cash Flow | -$37.4M | -$20.6M | -$15.6M | -$947K | -$5.5M | |
CLYM
Sector
Market Cap
$85.7M
$35.8M
Price % of 52-Week High
11%
45.38%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.81%
1-Year Price Total Return
-84.86%
-38.89%
Beta (5-Year)
--
0.662
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.28
200-day SMA
Sell
Level
$3.74
Bollinger Bands (100)
Sell
Level
1.2 - 2.2
Chaikin Money Flow
Buy
Level
461.5K
20-day SMA
Buy
Level
$1.26
Relative Strength Index (RSI14)
Sell
Level
48.72
ADX Line
Buy
Level
14
Williams %R
Neutral
Level
-63.1579
50-day SMA
Sell
Level
$1.31
MACD (12, 26)
Buy
Level
0.12
25-day Aroon Oscillator
Buy
Level
24
On Balance Volume
Neutral
Level
758.5K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
Stock Forecast FAQ
In the current month, CLYM has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CLYM average analyst price target in the past 3 months is $10.00.
-
Where Will Climb Bio Stock Be In 1 Year?
According to analysts, the consensus estimate is that Climb Bio share price will rise to $10.00 per share over the next 12 months.
-
What Do Analysts Say About Climb Bio?
Analysts are divided on their view about Climb Bio share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Climb Bio is a Sell and believe this share price will drop from its current level to $10.00.
-
What Is Climb Bio's Price Target?
The price target for Climb Bio over the next 1-year time period is forecast to be $10.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CLYM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Climb Bio is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of CLYM?
You can purchase shares of Climb Bio via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Climb Bio shares.
-
What Is The Climb Bio Share Price Today?
Climb Bio was last trading at $1.28 per share. This represents the most recent stock quote for Climb Bio. Yesterday, Climb Bio closed at $1.27 per share.
-
How To Buy Climb Bio Stock Online?
In order to purchase Climb Bio stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Adobe Stock a Bargain With AI Tools Driving Growth?
The share price of American computer software company Adobe (NASDAQ:ADBE)…
Is Palantir Stock a Millionaire Maker?
Palantir (NASDAQ:PLTR) has shot upward over the last year and…
Stock Ideas
Buy
71
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Sell
4
CABO alert for May 3
Cable One [CABO] is down 41.98% over the past day.
Buy
55
PDEX alert for May 3
Pro-Dex [PDEX] is down 32.02% over the past day.
Buy
91
TRUP alert for May 3
Trupanion [TRUP] is up 23.52% over the past day.
